MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, PRLD had $20,971K increase in cash & cash equivalents over the period. -$19,115K in free cash flow.

Cash Flow Overview

Change in Cash
$20,971K
Free Cash flow
-$19,115K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-19,725 -63,316
Depreciation and amortization
425 868
Noncash lease expense
383 767
Stock-based compensation
2,423 7,646
Amortization of premium and discount on marketable securities, net
49 134
Prepaid expenses and other current assets
-287 1,379
Deferred revenue
-0
Accounts payable
-2,429 -2,760
Accrued expenses and other liabilities
-367 -2,098
Operating lease liabilities
63 -100
Net cash used in operating activities
-19,115 -60,306
Purchases of marketable securities
0 34,127
Proceeds from maturities of marketable securities
40,091 107,901
Purchases of property and equipment
0 67
Net cash provided by investing activities
40,091 73,707
Payment of offering costs
0 0
Proceeds from the issuance of common stock under espp
0 92
Proceeds from the issuance of common stock in connection with the exercise of stock options
0 0
Payment of withholding taxes related to stock-based compensation to employees
5 7
Principal payments on finance lease liabilities
0 208
Net cash used in financing activities
-5 -123
Net increase (decrease) in cash, cash equivalents and restricted cash
20,971 13,278
Cash and cash equivalents at beginning of period
16,518 -
Cash and cash equivalents at end of period
50,767 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Prelude Therapeutics Inc (PRLD)

Prelude Therapeutics Inc (PRLD)